Amundi Asset Management US Inc. Has $120.94 Million Holdings in Align Technology, Inc. (NASDAQ:ALGN)

Amundi Asset Management US Inc. decreased its position in shares of Align Technology, Inc. (NASDAQ:ALGN) by 20.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 223,326 shares of the medical equipment provider’s stock after selling 57,448 shares during the period. Amundi Asset Management US Inc. owned 0.28% of Align Technology worth $120,938,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Allred Capital Management LLC acquired a new position in Align Technology during the 1st quarter worth $27,000. Atlas Capital Advisors LLC raised its position in shares of Align Technology by 150.0% during the first quarter. Atlas Capital Advisors LLC now owns 50 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 30 shares during the last quarter. Massmutual Trust Co. FSB ADV raised its position in shares of Align Technology by 226.7% during the first quarter. Massmutual Trust Co. FSB ADV now owns 49 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 34 shares during the last quarter. Prestige Wealth Management Group LLC raised its position in shares of Align Technology by 488.9% during the fourth quarter. Prestige Wealth Management Group LLC now owns 53 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 44 shares during the last quarter. Finally, CVA Family Office LLC acquired a new position in shares of Align Technology during the first quarter valued at about $30,000. 84.13% of the stock is owned by hedge funds and other institutional investors.

Shares of ALGN stock opened at $619.65 on Thursday. Align Technology, Inc. has a 1 year low of $279.83 and a 1 year high of $653.86. The business’s 50 day moving average is $602.21. The firm has a market capitalization of $49.04 billion, a price-to-earnings ratio of 107.77, a price-to-earnings-growth ratio of 2.98 and a beta of 1.69.

Align Technology (NASDAQ:ALGN) last announced its earnings results on Tuesday, April 27th. The medical equipment provider reported $2.49 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.02 by $0.47. Align Technology had a net margin of 16.27% and a return on equity of 14.65%. The company had revenue of $894.80 million for the quarter, compared to analyst estimates of $810.27 million. During the same period in the prior year, the business earned $0.73 earnings per share. Align Technology’s quarterly revenue was up 62.4% on a year-over-year basis. On average, equities research analysts anticipate that Align Technology, Inc. will post 8.9 EPS for the current year.

A number of research analysts have recently commented on the stock. Berenberg Bank raised shares of Align Technology from a “hold” rating to a “buy” rating and set a $683.00 price objective for the company in a research report on Thursday, April 22nd. Stifel Nicolaus upped their target price on shares of Align Technology from $650.00 to $750.00 and gave the company a “buy” rating in a research note on Thursday, April 29th. Piper Sandler upped their target price on shares of Align Technology from $700.00 to $735.00 and gave the company an “overweight” rating in a research note on Thursday, April 29th. Zacks Investment Research cut shares of Align Technology from a “strong-buy” rating to a “hold” rating and set a $575.00 target price on the stock. in a research note on Tuesday, April 6th. Finally, Credit Suisse Group upped their target price on shares of Align Technology from $693.00 to $715.00 and gave the company an “outperform” rating in a research note on Thursday, April 29th. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $676.64.

In other Align Technology news, CFO John Morici sold 6,863 shares of the stock in a transaction on Friday, May 21st. The shares were sold at an average price of $597.65, for a total value of $4,101,671.95. Following the sale, the chief financial officer now directly owns 3,040 shares in the company, valued at $1,816,856. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director C Raymond Larkin, Jr. sold 5,000 shares of the stock in a transaction on Friday, May 7th. The stock was sold at an average price of $598.70, for a total transaction of $2,993,500.00. Following the completion of the sale, the director now owns 30,987 shares in the company, valued at $18,551,916.90. The disclosure for this sale can be found here. Insiders sold 29,896 shares of company stock worth $18,146,757 over the last 90 days. 0.70% of the stock is currently owned by company insiders.

Align Technology Company Profile

Align Technology, Inc, a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services.

Further Reading: Swap

Institutional Ownership by Quarter for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related companies with MarketBeat.com's FREE daily email newsletter.